Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023 - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023

Description:

Research Beam added a report on “Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023” Enquiry about report: – PowerPoint PPT presentation

Number of Views:29

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023


1
PharmaPoint Multiple Myeloma - Global Drug
Forecast and Market Analysis to 2023
(Type, Mode of action, Crop Type and Geography) -
Size, Share, Global Trends, Company Profiles,
Demand, Insights, Analysis, Research, Report,
Opportunities, Segmentation and Forecast, 2013 -
2020
TELEPHONE 1 (503) 894-6022 E-MAIL
sales_at_researchbeam.com
Published on Oct 2014
2


Report Overview
  • Summary
  • The Multiple Myeloma (MM) market is currently
    dominated by Velcade and Revlimid, and the market
    is set to undergo substantial growth between 2013
    and 2023. The main drivers of growth will be the
    launch of monoclonal antibodies (mAbs) Empliciti
    and daratumumab, which will not only provide a
    new treatment option for MM patients, but will
    also lengthen the time between relapses, meaning
    that the duration of Revlimid and/or Velcade
    treatments will also be longer. Furthermore, the
    relatively mild safety profile of these mAbs and
    the significant efficacies demonstrated by these
    agents will mean that more MM patients will
    ultimately receive drug treatment. Label
    extensions of these mAbs, as well as of
    second-generation proteasome inhibitors ixazomib
    and Kyprolis, will further increase treatment
    options for these patients. The biggest
    constrainers of the MM market are the increasing
    cost-consciousness of healthcare providers, as
    the launch and subsequent label extensions of
    these pipeline agents will lead to a significant
    expense, which may impact uptake of these drugs.
    The patent expiries of Revlimid and Velcade will
    somewhat alleviate healthcare spending on
    multiple myeloma patients, which may assist in
    the uptake of mAbs and second-generation PIs in
    the multiple myeloma market.
  • Read More At http//www.researchbeam.com/pharmapo
    int-multiple-myeloma-global-drug-forecast-and-anal
    ysis-to-2023-market

3


Table of Content
1 Table of Contents 11 1.1 List of Tables 17 1.2
List of Figures 23 2 Introduction 25 2.1
Catalyst 25 2.2 Related Reports 26 3 Disease
Overview 27 3.1 Etiology and Pathophysiology
27 3.2 Staging Systems 30 4 Epidemiology 38 4.1
Disease Background 38 4.2 Risk Factors and
Comorbidities 39 5 Disease Management 62 5.1
Treatment Overview 62 5.2 Diagnosis 63 6
Competitive Assessment 93 6.1 Overview 93 6.2
Product Profiles - Proteasome Inhibitors 93
4


Table of Content
7 Unmet Need and Opportunity 121 7.1 Overview
121 7.2 Treatment of High-Risk Patients 121 8
Pipeline Assessment 128 8.1 Overview 128 8.2
Promising Drugs in Clinical Development 128 9
Current and Future Players 161 9.1 Overview and
Trends in Corporate Strategy 161 9.2 Company
Profiles 164 10 Market Outlook 175 10.1 Global
Markets 175 10.2 US 184 11 Appendix 211 11.1
Bibliography 211 11.2 Abbreviations 233 Enquire
At http//www.researchbeam.com/pharmapoint-multi
ple-myeloma-global-drug-forecast-and-analysis-to-2
023-market/enquire-about-report
5



FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/pharmapoint-multiple-m
yeloma-global-drug-forecast-and-analysis-to-2023-m
arket
Stay With Us
5933 NE Win Sivers Drive, 205, Portland, OR
97220 United States
TELEPHONE 1 (800) 910-6452 DIRECT 1 (503)
894-6022 E-MAIL sales_at_researchbeam.com
About PowerShow.com